Publication & Citation Trends
Publications
0 total
40 Blood-based proteomic and glycoproteomic biomarkers exhibit promising additivity in predicting response in checkpoint inhibitor treated lung cancer
Cited by 0
Semantic Scholar
741 Correlation between protein expression in immune cell populations and circulating glycopeptide biomarkers differs with response to checkpoint inhibitor treatment in advanced lung cancer
Cited by 0
Semantic Scholar
1694MO Novel serum glycoproteomic biomarkers predict response to nivolumab plus cabozantinib (NIVO+CABO) versus sunitinib (SUN) in advanced RCC (aRCC): Analysis from CheckMate 9ER
Cited by 2
Semantic Scholar
P1.21-18 Potential Role of Serum Glycoproteomics in Predicting irAEs in NSCLC Patients Treated with Immunotherapy
Cited by 0
Semantic Scholar
P1.21-19 Potential Utilization of Serum Glycoproteomics as a Biomarker to Predict Survival Outcomes and irAEs in Advanced NSCLC Treated with ICI OA
Cited by 0
Semantic Scholar
43 Harnessing the power of glycoproteomics: a cutting-edge approach for predicting treatment efficacy in metastatic melanoma with immune checkpoint inhibitors OA
Cited by 0
Semantic Scholar
Research Topics
Renal cell carcinoma treatment
(36)
Renal and related cancers
(24)
HER2/EGFR in Cancer Research
(23)
Cancer Genomics and Diagnostics
(22)
Cancer Immunotherapy and Biomarkers
(21)
Affiliations
Novartis (Switzerland)
Translational Genomics Research Institute
Mayo Clinic
Exelixis (United States)
Bristol-Myers Squibb (Germany)